Bone Biologics Corp Warrants financials
$4.06−5.58%
Close Sep 18, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$808.1K | -$805.1K | -$733.1K | -$715.3K | -$748.1K | -$1.0M | -$1.6M | -$951.0K | -$809.7K | -$903.5K | -$1.2M | -$2.1M |
| Net income | -$773.7K | -$766.0K | -$684.6K | -$666.7K | -$740.5K | -$1.0M | -$1.5M | -$4.2M | -$783.7K | -$866.0K | -$1.5M | -$1.9M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.43 | $-0.43 | $-0.38 | $-0.37 | $-1.33 | $-1.92 | $-1.86 | $-14.21 | $-4.02 | $-7.86 | $-36.59 | $-29.40 |
| EBITDA | -$808.1K | -$805.1K | -$733.1K | -$715.3K | -$748.1K | -$1.0M | -$1.6M | -$951.0K | -$809.7K | -$903.5K | -$1.2M | -$2.1M |
| Operating cash flow | -$518.4K | -$804.3K | -$714.8K | -$591.4K | -$458.9K | -$926.1K | -$1.4M | -$572.2K | -$895.9K | -$1.3M | -$2.0M | -$2.6M |
| Free cash flow | -$518.4K | -$804.3K | -$714.8K | -$591.4K | -$458.9K | -$926.1K | -$1.4M | -$572.2K | -$895.9K | -$1.3M | -$2.0M | -$2.6M |
| Diluted shares | 1.8M | 1.8M | 1.8M | 1.8M | 0.6M | 0.5M | 0.8M | 0.3M | 0.2M | 0.1M | 0.0M | 0.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.0M | $4.5M | $5.3M | $6.0M | $6.6M | $2.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $4.4M | $5.0M | $5.8M | $6.4M | $7.0M | $3.2M |
| Total liabilities | $512.0K | $309.4K | $418.6K | $334.3K | $406.1K | $251.2K |
| Shareholders' equity | $3.9M | $4.7M | $5.4M | $6.0M | $6.6M | $2.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology